TNF-α Blockade Inhibits Matrix Metalloproteinase 9-Mediated Collagenase Activity in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

[1]  M. Pirmohamed,et al.  TNF-α mediated keratinocyte expression and release of matrix metalloproteinase 9: putative mechanism of pathogenesis in Stevens-Johnson syndrome/ toxic epidermal necrolysis. , 2022, The Journal of investigative dermatology.

[2]  M. Noe,et al.  Systemic Interventions for Treatment of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Summary of a Cochrane Review. , 2022, JAMA dermatology.

[3]  Chun-Bing Chen,et al.  Evaluation of combination therapy with etanercept and systemic corticosteroids for Stevens-Johnson syndrome and toxic epidermal necrolysis: A multicenter observational study. , 2022, The journal of allergy and clinical immunology. In practice.

[4]  Coco Chu,et al.  Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. , 2022, Journal of the American Academy of Dermatology.

[5]  M. Noe,et al.  Medical Management of SJS/TEN Among North American Dermatologists. , 2021, Journal of the American Academy of Dermatology.

[6]  N. Sharma,et al.  Prognostic significance of matrix metalloproteinase 9 in COMET operated chronic ocular Stevens-Johnson syndrome , 2021, British Journal of Ophthalmology.

[7]  P. Kuo,et al.  Treating toxic epidermal necrolysis with systemic immunomodulating therapies: a systematic review and network meta-analysis. , 2020, Journal of the American Academy of Dermatology.

[8]  Ya-Chung Tian,et al.  Disseminated intravascular coagulation in Stevens-Johnson syndrome and toxic epidermal necrolysis. , 2020, Journal of the American Academy of Dermatology.

[9]  D. Granville,et al.  Proteases in Pemphigoid Diseases , 2019, Front. Immunol..

[10]  C. Overall,et al.  Granzyme B is elevated in autoimmune blistering diseases and cleaves key anchoring proteins of the dermal-epidermal junction , 2018, Scientific Reports.

[11]  H. Simon,et al.  Monocytes enhance neutrophil‐induced blister formation in an ex vivo model of bullous pemphigoid , 2018, Allergy.

[12]  Lan-Yan Yang,et al.  Randomized, controlled trial of TNF-&agr; antagonist in CTL-mediated severe cutaneous adverse reactions , 2018, The Journal of clinical investigation.

[13]  D. Granville,et al.  Granzyme B in skin inflammation and disease. , 2017, Matrix biology : journal of the International Society for Matrix Biology.

[14]  M. Schumacher,et al.  Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. , 2017, The Journal of investigative dermatology.

[15]  G. Haegeman,et al.  Bullous pemphigoid outcome is associated with CXCL10‐induced matrix metalloproteinase 9 secretion from monocytes and neutrophils but not lymphocytes , 2017, The Journal of allergy and clinical immunology.

[16]  Bosco K. Ho,et al.  Granzyme B promotes cytotoxic lymphocyte transmigration via basement membrane remodeling. , 2014, Immunity.

[17]  H. Nakauchi,et al.  Inhibition of plasmin attenuates murine acute graft-versus-host disease mortality by suppressing the matrix metalloproteinase-9-dependent inflammatory cytokine storm and effector cell trafficking , 2014, Leukemia.

[18]  G. Godeau,et al.  Possible involvement of gelatinase A (MMP2) and gelatinase B (MMP9) in toxic epidermal necrolysis or Stevens-Johnson syndrome , 2004, Archives of Dermatological Research.

[19]  W. Garner,et al.  Transforming Growth Factor-β- and Tumor Necrosis Factor-α-mediated Induction and Proteolytic Activation of MMP-9 in Human Skin* , 2001, The Journal of Biological Chemistry.